A prospective study on concurrent chemotherapy and thoracic three-dimensional radiotherapy for stage Ⅳ non-small cell lung cancer (3)- The impact of radiation dose to thoracic primary tumor on survival
10.3760/cma.j.issn.1004-4221.2012.01.008
- VernacularTitle:Ⅳ期非小细胞肺癌化疗同期胸部三维放疗的前瞻性临床研究(三)——不同放疗剂量对生存的影响
- Author:
Jinhua LONG
;
Bing LU
;
Weiwei OUYANG
;
Shengfa SU
;
Yinxiang HU
;
Gang WANG
;
Huiqin LI
;
Xiaoxiao CHEN
;
Xiuyun GANG
;
Bo ZHANG
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small cell lung/concurrent chemoradiotherapy;
Radiotherapy,three-dimensional;
Radiotherapy dose;
Prognosis
- From:
Chinese Journal of Radiation Oncology
2012;21(1):23-27
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the effect of radiation dose on survival for stage Ⅳ non-small cell lung cancer (NSCLC) treated with concurrent chemotherapy and thoracic three-dimensional radiotherapy (CCTTRT).Methods From Jan.2003 to Jul.2010,201 Stage Ⅳ NSCLC patients were enrolled.Nineteen patients who received only one cycle chemotherapy were not included in survival analysis.Of the 182 patients eligible for survival analysis,all patients received platinum-based chemotherapy of two drugs.The median number of cycles was 4.The median dose to planning target volume of primary tumor ( DTPTV )was 63 Gy. Survival was calculated by Kaplan-Meier method and compared using the Logrank. Cox regression models were used to examine the effect of DTPTV on overall survival.ResultsThe follow-up rate of 201 patients was 97.5%.with 201,170 and 134 patients finished < 1,1 -2 and ≥3 years' follow-up.The 1-,2-,3-year overall survival rate and median survival time was 20%,14%,0% and 7.1 months;27%,10%,3% and 9.6 months;and 59%,22%,16% and 14.9 months,respectively for patients treated with DTPTV < 45.0 Gy,45.0 - 62.1 Gy and ≥63.0 Gy,respectively ( χ2 =27.88,P =0.000 ) ;43%,19%,0%and 1 1 months and 2 0 %,1 1%,5 % and 8 months,respectively for those received 2 - 3 cycles of chemotherapy and radiation dose ≥63 Gy and < 63 Gy,respectively (χ2 =2.99,P =0.084) ;66%,23%,19% and 16 months and 29%,12%,0% and 8.8 months,respectively for those received 4 - 5 cycles chemotherapy and radiation dose ≥ 63 Gy and < 63 Gy,respectively (χ2=15.87,P=0.000).No significant difference was found for patients received 2 - 3 cycles chemotherapy concurrently with DTP,Tv ≥63 Gy and 4 -5 cycles chemotherapy concurrently with DTPTV <63 Gy,respectively (χ2 =1.93,P =0.165).Multivariate analysis showed that 4 -5 cycles chemotherapy concurrently with DTPTv ≥63 Gy ( β =0.243,P =0.019),and improved KPS after treatment ( β =1.268,P =0.000) were independent favorable factors for survival.ConclusionChemotherapy concurrent with CCTTRT can prolong survival time of patients with stage Ⅳ NSCLC,especially for those treated with DTPTV ≥63 Gy.